Elizabeth S. Duke

Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 17, 2026

Evaluating "Brain Permeability": A Critical Issue for the Development of Therapeutic Agents for Primary and Metastatic Brain Tumors.

Journal: Neuro-oncology

Published: November 26, 2025

Evaluating "brain permeability": A critical issue for the development of therapeutic agents for primary and metastatic brain tumors.

Journal: Neuro-oncology

Published: November 26, 2025

US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 25, 2024

Molecular-targeted therapy for childhood low-grade glial and glioneuronal tumors.

Journal: Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery

Published: March 20, 2024

A brave new framework for glioma drug development.

Journal: The Lancet. Oncology

Published: February 28, 2024

Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 03, 2023

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 17, 2023

Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development.

Journal: Cancer discovery

Published: December 02, 2022

Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival.

Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival.

Evaluating "Brain Permeability": A Critical Issue for the Development of Therapeutic Agents for Primary and Metastatic Brain Tumors.

Evaluating "Brain Permeability": A Critical Issue for the Development of Therapeutic Agents for Primary and Metastatic Brain Tumors.

Evaluating "brain permeability": A critical issue for the development of therapeutic agents for primary and metastatic brain tumors.

Evaluating "brain permeability": A critical issue for the development of therapeutic agents for primary and metastatic brain tumors.

US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy.

US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy.

Molecular-targeted therapy for childhood low-grade glial and glioneuronal tumors.

Molecular-targeted therapy for childhood low-grade glial and glioneuronal tumors.

A brave new framework for glioma drug development.

A brave new framework for glioma drug development.

Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium.

Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium.

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.

Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development.

Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development.

FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.

FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.

Neurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive Impact.

Neurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive Impact.